Questions:

01:08: How have your personal experiences shaped your understanding of evidence, access, and impact in health policy?

03:24: What core principles have remained constant throughout your work across advocacy, government, and consulting in health policy?

05:20: Can you share an example of a well-designed policy that failed at the implementation stage, and what you learned from it?

06:26: What lessons from implementing the ACA have shaped your approach to structuring practical, workable health policy frameworks today?

08:45: If you were designing a US HTA framework today, what would you build differently to make it work in practice?

11:28: What are your reflections on ICER’s current assessment process, and how could it be improved to make its findings more useful and actionable across the healthcare system?

14:25: Why does the US continue to struggle to fully integrate evidence generation into its pricing and access frameworks?

16:35: If you could design an incentive structure to encourage pharmaceutical companies to share their data, what would it look like and how would you make it work in practice?

20:03: What do you see as the most effective way to align FDA and CMS around patient-centered access?

25:11: If you could design a structured communication process between CMS and industry, what would it look like?

27:28: Can you share an example of how stakeholder feedback directly improved CMS implementation efforts?

35:06: What emerging policy and regulatory trends will most influence pharma market access and RWE over the next decade, and which are still being underestimated?

39:57: Amid rising costs and solvency challenges, what gives you confidence that the US can bend the healthcare cost curve without stifling innovation?

Kristi Martin

Director, Camber Collective

Kristi Martin brings over 20 years of experience shaping health policy through practical, impactful solutions. Currently a Director at Camber Collective, she pairs analytic rigor with a human-centered approach to advance strategies that improve health and well-being. She guides mission-driven organizations through complex health policy landscapes through her own firm, Highway 136 Consulting, which was founded in 2020.

Kristi’s career spans government, philanthropy, and consulting – always focused on making healthcare better and fairer. Most recently, she served as Chief of Staff for Medicare at the Centers for Medicare & Medicaid Services (CMS), where she led strategy and execution for major initiatives under the Inflation Reduction Act, including Medicare drug price negotiations.

Previously, Kristi was Vice President for Health Care at Arnold Ventures, managing their portfolio to lower prescription drug costs. As Managing Director at Waxman Strategies, she provided strategic counsel to foundations and advocacy organizations on issues ranging from prescription drug pricing to women’s health. Earlier, she played a key role in implementing provisions of the Affordable Care Act, advising senior officials, and coordinating policy across federal agencies at the Department of Health and Human Services, CMS, and the Office of Personnel Management. Her federal service across these agencies as well as Government Accountability Office and National Institutes of Health gave her a strong foundation in policy development and implementation. Her roots in DC are in patient advocacy as she started her career with Easter Seals and the American Cancer Society.

Known for turning bold ideas into action, Kristi has advised the White House, represented US interests internationally, and built consensus among diverse stakeholders. She holds a Master of Public Administration from George Washington University and earned both a master’s and bachelor’s degree from the University of Kentucky.

Hosted on Acast. See acast.com/privacy for more information.

In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Jason Shafrin, Senior Managing Director, Center for Health Economics and Policy, FTI Consulting.

Questions:

00:00: Introduction

01:15: You’ve worked across government, pharma, consulting, NGOs, and academia. What ties it all together, and what are you trying to solve now?

03:35: Was there a moment that drew you to health economics, or was it a gradual pull?

05:47: You’ve written on value frameworks and outcomes for reimbursement. If you could redesign HTA from scratch, what would you toss and what would you keep?

09:53: You’ve said incentives drive behavior, and competing incentives are a constant challenge. What’s the most misaligned incentive in healthcare today – and who does it hurt most?

15:19: With growing scrutiny of RWE and digital health, is oversight enabling or stifling innovation?

17:54: What’s one policy or regulation you believe is well-intentioned, but has led to poor health or economic outcomes?

22:31: On July 31, President Trump asked 17 pharma companies to match US drug prices to other developed nations. As a health economist, do you think this will work?

27:14: Rapid Fire Questions

Jason Shafrin

Senior Managing Director, Center for Health Economics and Policy, FTI Consulting

Jason Shafrin, PhD, is a Senior Managing Director at FTI Consulting's Center for Healthcare Economics and Policy. Dr Shafrin has over 20 years of health economics research experience serving as trusted advisor and expert to a wide variety of healthcare and life sciences companies, governments and non-governmental organizations (NGOs). Dr Shafrin is an Adjunct Professor at the University of Southern California, the former Director of Research at the Innovation and Value Initiative and the Founder and Editor of the Healthcare Economist blog. Dr Shafrin is an expert in applied economics with a specialty in health economics research. Over his career, he has developed novel methodological approaches, advanced quantitative analyses and innovative modeling to address some of the most difficult health economics problems and provide evidence-based solutions for clients across the healthcare industry. His work has assisted clients in addressing policy changes, navigating regulatory processes, evaluating pricing, value and outcomes and supporting innovation and transformative change. Dr Shafrin’s extensive experience includes projects on value assessment, alternative payment model design, discrete choice experiment survey, real-world data analysis, and digital medicine.

Hosted on Acast. See acast.com/privacy for more information.